Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant609 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00412425 | Palonosetron for Prevention of Biochemotherapy Induced Nausea and Vomiting | completed | Phase 1 / Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | May 4, 2012 | clinicaltrials |
| NCT00483301 | A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma | completed | Phase 2 | 34 | Mt. Sinai Medical Center, MiamiOTHER | 1 | May 3, 2012 | clinicaltrials |
| NCT00616564 | Phase II Trial of (IL-2) With Priming and (GM-CSF) in Patients With Advanced Melanoma | completed | Phase 2 | 36 | Mt. Sinai Medical Center, MiamiOTHER | 1 | May 3, 2012 | clinicaltrials |
| NCT00369395 | A Study of Volociximab in Metastatic Melanoma | terminated | Phase 2 | 19 | AbbottINDUSTRY | 1 | Apr 27, 2012 | clinicaltrials |
| NCT00035165 | EPO906 Therapy in Patients With Advanced Melanoma | completed | Phase 2 | 51 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 25, 2012 | clinicaltrials |
| NCT01584115 | Clinical Trial of a Therapeutic Vaccine With NY-ESO-1 in Combination With the Adjuvant Monophosphoryl Lipid A (MPLA) | unknown | Phase 1 / Phase 2 | 15 | Instituto de Investigação em ImunologiaOTHER | 1 | Apr 25, 2012 | clinicaltrials |
| NCT01048554 | Temozolomide Plus Bevacizumab in Patients With Metastatic Melanoma Involving the Central Nervous System(MEL0107) | completed | Phase 2 | 34 | Mt. Sinai Medical Center, MiamiOTHER | 1 | Apr 19, 2012 | clinicaltrials |
| NCT00138229 | Cyclophosphamide and Fludarabine Followed By an Autologous Lymphocyte Infusion and Interleukin-2 in Treating Patients With Refractory or Recurrent Metastatic Melanoma | terminated | Phase 2 | 6 | National Institutes of Health Clinical Center (CC)NIH | 1 | Mar 29, 2012 | clinicaltrials |
| NCT00287131 | Adoptive Cell Therapy Following Non-myeloablate Chemotherapy in Metastatic Melanoma Patients | unknown | Phase 2 | 70 | Sheba Medical CenterOTHER_GOV | 1 | Mar 29, 2012 | clinicaltrials |
| NCT00316901 | Positron Emission Tomography and CT Scan in Predicting Response in Patients With Metastatic Melanoma or Kidney Cancer Who Are Undergoing Cellular Adoptive Immunotherapy on a Surgery Branch Clinical Trial | completed | Phase 2 | 70 | National Institutes of Health Clinical Center (CC)NIH | 1 | Mar 15, 2012 | clinicaltrials |
| NCT00925314 | A Study of Transgenic Lymphocyte Immunization (TLI) Against Telomerase in Subjects With Stage III Melanoma | unknown | Phase 2 | 20 | Cosmo BioscienceINDUSTRY | 1 | Feb 13, 2012 | clinicaltrials |
| NCT01409187 | IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic Melanoma | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jan 26, 2012 | clinicaltrials |
| NCT00002860 | SWOG-9430: Surgery in Treating Patients With Metastatic Melanoma | completed | Phase 2 | 77 | SWOG Cancer Research NetworkNETWORK | 1 | Jan 13, 2012 | clinicaltrials |
| NCT00006233 | Combination Chemotherapy, Total-Body Irradiation, Peripheral Stem Cell Transplantation, and Lymphocyte Infusion in Treating Patients With Stage IV Melanoma | completed | Phase 2 | — | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 30, 2011 | clinicaltrials |
| NCT00006385 | Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma | completed | Phase 2 | — | Eastern Cooperative Oncology GroupNETWORK | 1 | Nov 8, 2011 | clinicaltrials |
| NCT01092585 | Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH | unknown | Phase 2 | 27 | Genta IncorporatedINDUSTRY | 1 | Nov 8, 2011 | clinicaltrials |
| NCT00060710 | CP-461 in the Treatment of Patients With Advanced Melanoma | terminated | Phase 2 | 35 | Astellas Pharma IncINDUSTRY | 1 | Oct 17, 2011 | clinicaltrials |
| NCT00204581 | Intralesional Treatment With Interleukin-2 (Proleukin) in Soft Tissue Melanoma Metastases | completed | Phase 2 | 51 | University Hospital TuebingenOTHER | 1 | Aug 19, 2011 | clinicaltrials |
| NCT00003646 | Gene Therapy in Treating Patients With Stage III or Stage IV Melanoma | completed | Phase 2 | 78 | VicalINDUSTRY | 1 | Jul 7, 2011 | clinicaltrials |
| NCT00044356 | Phase II Trial of Allovectin-7® for Metastatic Melanoma | completed | Phase 2 | 133 | VicalINDUSTRY | 1 | Jul 7, 2011 | clinicaltrials |
| NCT00658437 | CY503 for the Treatment of Malignant Melanoma Stage IV After Failure of Prior Therapy | completed | Phase 2 | 31 | Cytavis Biopharma GmbHINDUSTRY | 1 | Jun 8, 2011 | clinicaltrials |
| NCT00602199 | ABT-510 in Treating Patients With Metastatic Melanoma | completed | Phase 2 | 42 | Mayo ClinicOTHER | 0 | May 16, 2011 | clinicaltrials |
| NCT00003091 | High-Dose Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer or Melanoma | completed | Phase 2 | 40 | Hoag Memorial Hospital PresbyterianOTHER | 1 | May 12, 2011 | clinicaltrials |
| NCT00033228 | Vaccine Therapy in Treating Patients With Stage IV Melanoma | completed | Phase 1 / Phase 2 | 19 | Mannkind CorporationINDUSTRY | 1 | May 12, 2011 | clinicaltrials |
| NCT00261404 | TNFerade™ Biologic Plus Radiation for Metastatic Melanoma | completed | Phase 2 | — | GenVecINDUSTRY | 1 | May 12, 2011 | clinicaltrials |
| NCT00002733 | Biological Therapy in Treating Patients With Metastatic Cancer | completed | Phase 2 | 30 | Hoag Memorial Hospital PresbyterianOTHER | 1 | May 11, 2011 | clinicaltrials |
| NCT00496223 | A Phase I/II Study of Sunitinib and Dacarbazine | terminated | Phase 1 / Phase 2 | 11 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 23, 2011 | clinicaltrials |
| NCT01168050 | Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.(NILOMEL) | unknown | Phase 2 | 25 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Feb 8, 2011 | clinicaltrials |
| NCT00050102 | Comparison Study of MDX-010 (CTLA-4) Alone and Combined With DTIC in the Treatment of Metastatic Melanoma | completed | Phase 2 | — | Bristol-Myers SquibbINDUSTRY | 1 | Jan 28, 2011 | clinicaltrials |
| NCT00881049 | Trial of Imatinib (Gleevec®) in Selected Patients With Metastatic Melanoma | completed | Phase 2 | 1 | Peking UniversityOTHER | 1 | Jan 17, 2011 | clinicaltrials |
| NCT00746746 | A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma | unknown | Phase 2 | 30 | Ochsner Health SystemOTHER | 1 | Jan 13, 2011 | clinicaltrials |
| NCT00623402 | Combined Treatment of Sorafenib and Pegylated Interferon α2b in Stage IV Metastatic Melanoma(SoraPeg) | completed | Phase 2 | 55 | University Hospital Schleswig-HolsteinOTHER | 1 | Jan 12, 2011 | clinicaltrials |
| NCT00651703 | Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma Patients | completed | Phase 2 | 21 | Cytos Biotechnology AGINDUSTRY | 1 | Nov 15, 2010 | clinicaltrials |
| NCT00811759 | Sorafenib and Temozolomide in Treating Patients With Stage III or Stage IV Melanoma | unknown | Phase 1 / Phase 2 | 58 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Oct 7, 2010 | clinicaltrials |
| NCT00327600 | Safety and Efficacy Trial of Imexon Plus DTIC in Advanced Malignant Melanoma | completed | Phase 1 / Phase 2 | 68 | AmpliMed CorporationINDUSTRY | 1 | Sep 15, 2010 | clinicaltrials |
| NCT00609011 | Phase 1 Study of MPC-6827 and Temozolomide in Metastatic Melanoma | completed | Phase 1 / Phase 2 | 22 | Myrexis Inc.INDUSTRY | 1 | Aug 23, 2010 | clinicaltrials |
| NCT00735332 | Efficacy Study of TLN-232 in Patients With Recurring Metastatic Melanoma | terminated | Phase 2 | 49 | Thallion PharmaceuticalsINDUSTRY | 2 | Aug 5, 2010 | clinicaltrials |
| NCT00153569 | Multiepitope Peptide Vaccination in Melanoma | unknown | Phase 2 | 25 | Charite University, Berlin, GermanyOTHER | 1 | May 26, 2010 | clinicaltrials |
| NCT00002786 | Biological Therapy in Treating Patients With Metastatic Melanoma | completed | Phase 1 / Phase 2 | 20 | Fred Hutchinson Cancer CenterOTHER | 1 | May 10, 2010 | clinicaltrials |
| NCT00610389 | Phase II Study With Immunotherapy With Dendritic Cells and Tumor Infiltrating Lymphocytes in Solid Tumors | unknown | Phase 2 | 27 | Clinica Universidad de Navarra, Universidad de NavarraOTHER | 1 | May 10, 2010 | clinicaltrials |
| NCT00197912 | Dendritic Cell Based Therapy of Malignant Melanoma | completed | Phase 1 / Phase 2 | 25 | Herlev HospitalOTHER | 1 | Apr 26, 2010 | clinicaltrials |
| NCT00289640 | Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma | completed | Phase 2 | 210 | Bristol-Myers SquibbINDUSTRY | 10 | Mar 2, 2010 | clinicaltrials |
| NCT00991250 | SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma | unknown | Phase 2 | 140 | SentoClone ABINDUSTRY | 1 | Feb 5, 2010 | clinicaltrials |
| NCT00794235 | Monocentric Pilot Study Investigating the Metabolic Activity of Melanoma in Vivo During Sorafenib and Dacarbazine | completed | Phase 2 | 12 | University of ZurichOTHER | 1 | Jan 8, 2010 | clinicaltrials |
| NCT00813449 | Safety Study of Combined Chemotherapy and Endostar to Untreated Patients With Advanced Melanoma(melanoma) | unknown | Phase 2 | 140 | Simcere Pharmaceutical Co., LtdOTHER | 1 | Dec 8, 2009 | clinicaltrials |
| NCT00116597 | Active Specific Intranodal Immunotherapy of Recombinant Vaccinia Virus in Locally Advanced to Metastatic Melanoma | completed | Phase 1 / Phase 2 | 15 | University Hospital, Basel, SwitzerlandOTHER | 1 | Dec 2, 2009 | clinicaltrials |
| NCT00243529 | Peptide-pulsed vs. RNA-transfected Dendritic Cell Vaccines in Melanoma Patients | completed | Phase 1 / Phase 2 | 64 | Radboud University Medical CenterOTHER | 1 | Sep 29, 2009 | clinicaltrials |
| NCT00963664 | Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma | withdrawn | Phase 2 | 250 | NeoPlas InnovationOTHER | 1 | Sep 9, 2009 | clinicaltrials |
| NCT00911443 | Thymosin Alpha 1, Interferon Alpha, or Both, in Combination With Dacarbazine in Patients With Malignant Melanoma | completed | Phase 2 | 488 | sigma-tau i.f.r. S.p.A.INDUSTRY | 8 | Jul 9, 2009 | clinicaltrials |
Data updated 22 days agoSource updated May 4, 2012source: clinicaltrials